| Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: Results from the PREVENT study. | |
| | |
MedLine Citation:
|
PMID: 20801464 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
This secondary analysis from the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) study compared the efficacy of venlafaxine ER and fluoxetine for the prevention of recurrence in patients with a history of recurrent major depressive disorder (MDD). Patients received double-blind treatment with venlafaxine ER (75-300 mg/d) or fluoxetine (20-60 mg/d) for 10 weeks (acute phase). Responders (17-item Hamilton Rating Scale for Depression [HAM-D(17)] score ≤12 and ≥50% reduction from baseline) continued on the same treatment during the 6-month continuation phase. At the start of the first and second 12-month maintenance phases, venlafaxine ER responders were randomly assigned to receive venlafaxine ER or placebo, whereas patients receiving fluoxetine continued to receive fluoxetine throughout both maintenance phases. The primary outcome was time to recurrence (HAM-D(17) > 12, reduction in HAM-D(17) score ≤ 50% from acute baseline, and meeting DSM-IV criteria for a diagnosis of MDD), which was assessed using Kaplan-Meier estimates. Using the primary definition of recurrence, the estimated probability of not experiencing a recurrence was 71.9% for venlafaxine ER (n = 160) and 55.8% for fluoxetine (n = 99) across 24 months of maintenance treatment. For this primary analysis, the overall effect of venlafaxine ER treatment was not statistically significant (p = 0.399) compared with fluoxetine; however, a significant treatment-by-time interaction was observed (p = 0.034). No significant between-group differences were observed with any of the secondary efficacy variables. Venlafaxine ER and fluoxetine were similarly well tolerated across 2 years of maintenance-phase therapy. |
| | |
Authors:
|
Michael E Thase; Alan Gelenberg; Susan G Kornstein; James H Kocsis; Madhukar H Trivedi; Philip Ninan; Thomas Li; Ron Pedersen; Martin Keller |
Related Documents
:
|
15738744 - Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepi... 12177584 - Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine... 9476744 - Efficacy of once-daily venlafaxine extended release (xr) for symptoms of anxiety in dep... 11597824 - Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. 7701244 - Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors. 19396774 - Clinical efficacy of a ginkgo biloba extract in the topical treatment of allergic conju... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of psychiatric research Volume: 45 ISSN: 1879-1379 ISO Abbreviation: J Psychiatr Res Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-02-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0376331 Medline TA: J Psychiatr Res Country: England |
Other Details:
|
Languages: eng Pagination: 412-20 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
University of Pennsylvania, Philadelphia, PA, United States. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Psychopathology in offspring from families of alcohol dependent female probands: a prospective study...
Next Document: Cytotoxic triterpenoid saponins acylated with monoterpenic acids from fruits of Gleditsia caspica De...